Literature DB >> 21562488

Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

E D Kharasch1, A Francis, A London, K Frey, T Kim, J Blood.   

Abstract

Systemic and oral clearances of alfentanil (ALF) are in vivo probes for hepatic and first-pass cytochrome P450 (CYP) 3A. Both ALF single-point plasma concentrations and miosis are surrogates for area under the concentration-time curve (AUC) and clearance and are minimal and noninvasive CYP3A probes. This investigation determined ALF sensitivity for detecting graded CYP3A induction and compared it with that of midazolam (MDZ). Twelve volunteers (sequential crossover) received 0, 5, 10, 25, or 75 mg oral rifampin for 5 days. MDZ and ALF were given intravenously and orally on sequential days. Dark-adapted pupil diameter was measured with blood sampling. Graded rifampin decreased plasma MDZ AUCs to 83, 76, 62, and 59% (intravenous (i.v.)) and 78, 66, 39, and 24% (oral) of control. Hepatic and first-pass CYP3A induction were detected comparably by plasma MDZ and ALF AUCs. Single ALF concentrations detected all CYP3A induction, whereas MDZ was less sensitive. ALF miosis detected induction of first-pass but not hepatic CYP3A.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21562488      PMCID: PMC3560934          DOI: 10.1038/clpt.2011.59

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  49 in total

1.  An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity.

Authors:  Janyce F Rogers; Mario L Rocci; David B Haughey; Joseph S Bertino
Journal:  Clin Pharmacol Ther       Date:  2003-03       Impact factor: 6.875

2.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Authors:  Thorir D Bjornsson; John T Callaghan; Heidi J Einolf; Volker Fischer; Lawrence Gan; Scott Grimm; John Kao; S Peter King; Gerald Miwa; Lan Ni; Gondi Kumar; James McLeod; R Scott Obach; Stanley Roberts; Amy Roe; Anita Shah; Fred Snikeris; John T Sullivan; Donald Tweedie; Jose M Vega; John Walsh; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

3.  Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects.

Authors:  Janyce F Rogers; Anne N Nafziger; Angela D M Kashuba; Daniel S Streetman; Mario L Rocci; Edna F Choo; Grant R Wilkinson; Joseph S Bertino
Journal:  J Clin Pharmacol       Date:  2002-10       Impact factor: 3.126

4.  Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.

Authors:  Evan D Kharasch; Christine Hoffer; Alysa Walker; Pamela Sheffels
Journal:  Clin Pharmacol Ther       Date:  2003-03       Impact factor: 6.875

5.  In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.

Authors:  Y S Lin; G F Lockwood; M A Graham; W R Brian; C M Loi; M R Dobrinska; D D Shen; P B Watkins; G R Wilkinson; E D Kharasch; K E Thummel
Journal:  Pharmacogenetics       Date:  2001-12

Review 6.  Problems and perspectives of phenotyping for drug-metabolizing enzymes in man.

Authors:  M Zaigler; I Tantcheva-Poór; U Fuhr
Journal:  Int J Clin Pharmacol Ther       Date:  2000-01       Impact factor: 1.366

7.  Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry.

Authors:  Thomas Kim; Amy London; Evan D Kharasch
Journal:  J Pharm Biomed Anal       Date:  2011-03-05       Impact factor: 3.935

8.  Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein.

Authors:  Christoph Wandel; Richard Kim; Margaret Wood; Alastair Wood
Journal:  Anesthesiology       Date:  2002-04       Impact factor: 7.892

9.  Physiologic and temporal variation in hepatic elimination of midazolam.

Authors:  U Klotz; G Ziegler
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

10.  The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.

Authors:  J Christopher Gorski; Suda Vannaprasaht; Mitchell A Hamman; Walter T Ambrosius; Melissa A Bruce; Barbara Haehner-Daniels; Stephen D Hall
Journal:  Clin Pharmacol Ther       Date:  2003-09       Impact factor: 6.875

View more
  11 in total

1.  Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers.

Authors:  Arne Kristian Skulberg; Ida Tylleskar; Turid Nilsen; Sissel Skarra; Øyvind Salvesen; Trond Sand; Thorsteinn Loftsson; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2018-03-22       Impact factor: 2.953

2.  Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.

Authors:  E D Kharasch; D Whittington; D Ensign; C Hoffer; P S Bedynek; S Campbell; K Stubbert; A Crafford; A London; T Kim
Journal:  Clin Pharmacol Ther       Date:  2012-03-07       Impact factor: 6.875

3.  Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil.

Authors:  Ida Tylleskar; Arne Kristian Skulberg; Sissel Skarra; Turid Nilsen; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2018-08-24       Impact factor: 2.953

4.  Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.

Authors:  Joanna C Masters; Denise M Harano; Howard E Greenberg; Shirley M Tsunoda; In-Jin Jang; Joseph D Ma
Journal:  Ther Drug Monit       Date:  2015-02       Impact factor: 3.681

5.  Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.

Authors:  Evan D Kharasch; Kristi Stubbert
Journal:  Drug Metab Dispos       Date:  2013-09-25       Impact factor: 3.922

6.  A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions.

Authors:  Sebastian Frechen; Juri Solodenko; Thomas Wendl; André Dallmann; Ibrahim Ince; Thorsten Lehr; Jörg Lippert; Rolf Burghaus
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-05-24

7.  Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.

Authors:  Ryuta Asaumi; Kota Toshimoto; Yoshifusa Tobe; Kenta Hashizume; Ken-Ichi Nunoya; Haruo Imawaka; Wooin Lee; Yuichi Sugiyama
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-02-05

8.  PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.

Authors:  Nina Hanke; Sebastian Frechen; Daniel Moj; Hannah Britz; Thomas Eissing; Thomas Wendl; Thorsten Lehr
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-09-07

9.  Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin.

Authors:  Justin D Lutz; Brian J Kirby; Lu Wang; Qinghua Song; John Ling; Benedetta Massetto; Angela Worth; Brian P Kearney; Anita Mathias
Journal:  Clin Pharmacol Ther       Date:  2018-04-19       Impact factor: 6.875

Review 10.  Drug Interactions With New Synthetic Opioids.

Authors:  Clara Pérez-Mañá; Esther Papaseit; Francina Fonseca; Adriana Farré; Marta Torrens; Magi Farré
Journal:  Front Pharmacol       Date:  2018-10-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.